TOFIDENCE

This brand name is authorized in Austria, Estonia, France, Italy, Lithuania.

Active ingredients

The drug TOFIDENCE contains one active pharmaceutical ingredient (API):

1	Tocilizumab UNII I031V2H011 - TOCILIZUMAB
	Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.
	Read more about Tocilizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC07	Tocilizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3079403, 3079414, 3079425, 3079436, 3079447, 3079458
FR	Base de données publique des médicaments	66782228
IT	Agenzia del Farmaco	051302014, 051302026, 051302038, 051302040, 051302053, 051302065
LT	Valstybinė vaistų kontrolės tarnyba	1100120, 1100121, 1100122, 1100123, 1100124, 1100125